Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | STAT6 | P42226 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353254 | 0.89 | — | — | |
| SCHEMBL9339249 | 0.79 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL42141 | 0.76 | FFAR3 (0.52) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL12145486 | 0.75 | — | — | |
| SCHEMBL18185901 | 0.75 | — | — | |
| SCHEMBL28179071 | 0.74 | FFAR3 (0.50) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL15522635 | 0.74 | FFAR3 (0.50) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL4014347 | 0.72 | — | — | |
| SCHEMBL16369860 | 0.72 | FFAR3 (0.48) | FFAR3MAPK1TP53NFKB1CYP2C19 | |
| SCHEMBL9825220 | 0.72 | TRPA1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-0991690-B1 | PROCESS FOR PREPARATION OF A DENDRITIC POLYOL | PERSTORP AB (SE) | 2004-08-04 | — | — | EP | disclosed |
| US-6211329-B1 | POLYETHER STAR POLYMER | PERSTORP AB (SE) | 2001-04-03 | — | — | US | disclosed |
| EP-0247472-B1 | PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID DERIVATIVES | BAYER AG (DE) | 1992-02-12 | — | — | EP | disclosed |
| EP-0247472-A2 | Process for the preparation of carboxylic acid derivatives | BAYER AG (DE) | 1987-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | FFAR3 4772/4885MAPK1 940/4885TP53 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.